Niacinamide is the water-soluble form of vitamin B3. In aesthetic practice, it has one of the broader clinical evidence bases of any topical active, with randomised controlled trials supporting use for hyperpigmentation, inflammatory acne, skin barrier repair, and rosacea. It is stable in formulation, well tolerated, and available without prescription at clinically effective concentrations.
What Niacinamide Is and How It Acts on Skin
Niacinamide is the amide form of nicotinic acid. Unlike niacin, it does not cause cutaneous vasodilation or flushing, which makes it well suited to topical application across all phototypes.
Its mechanisms of action are multiple and reasonably well characterised at this point in the literature.
Inhibition of melanosome transfer. Niacinamide does not inhibit melanin synthesis at the melanocyte. It suppresses the transfer of melanosomes from melanocytes to adjacent keratinocytes. This means its depigmenting effect is not permanent if the ingredient is discontinued, and it does not produce the paradoxical hyperpigmentation sometimes seen with aggressive depigmenting agents. The distinction matters for treatment planning.
Ceramide synthesis upregulation. Topical niacinamide upregulates ceramide expression in the stratum corneum. Ceramides are the lipid class most directly responsible for barrier integrity and transepidermal water loss (TEWL) control. This underlies its relevance in rosacea and in patients with compromised barrier function.
Anti-inflammatory signalling. Niacinamide suppresses proinflammatory cytokine activity and reduces sebaceous gland output. Both pathways contribute to efficacy in inflammatory acne vulgaris.
NAD+ precursor activity. Niacinamide is a precursor to NAD+, a coenzyme involved in DNA repair and cellular energy metabolism. This pathway is thought to contribute to photoprotection at oral supplementation doses. The clinical magnitude of this effect from topical-only application, at standard cosmeceutical concentrations, is still being characterised.
Niacinamide for Hyperpigmentation and Melasma
Hyperpigmentation is one of the most common presentations across UK aesthetic consultations. The evidence base for niacinamide in this indication is among the strongest in the cosmeceutical category.
The foundational clinical comparison is a randomised, double-blind controlled trial comparing 4% niacinamide cream with 4% hydroquinone cream in 27 patients with facial melasma over eight weeks (Navarrete-Solís et al., 2011). Both treatments produced statistically significant reductions in mMASI score. The niacinamide arm showed fewer adverse effects, specifically less erythema and desquamation. The authors concluded that 4% niacinamide represents a clinically viable alternative to hydroquinone with a more favourable tolerability profile.
This finding has been substantiated by more recent work. A 2025 randomised controlled trial published in the Journal of Cosmetic Dermatology compared a serum containing 5% niacinamide, combined with tranexamic acid, stabilised vitamin C, and hydroxy acids, against 4% hydroquinone in 60 women with facial melasma. Both arms produced significant improvement at 12 weeks. The multi-ingredient arm was again better tolerated, with no cases of exogenous ochronosis in the active group.
The clinical implication for UK practice is specific. Hydroquinone at 4% is prescription-only in the UK. Niacinamide at 4-5% is available in cosmeceutical-grade formulations without a prescriber. Where patients present with mild-to-moderate pigmentation and tolerability is a concern, the evidence supports niacinamide as a clinically rational component of a homecare protocol. It should not be positioned as equivalent to prescription-strength depigmenting therapy in moderate-to-severe or recalcitrant melasma.
Practitioners managing hyperpigmentation should also be familiar with the NICE guidelines on acne, which address post-inflammatory hyperpigmentation (PIH) as a sequela of acne vulgaris and inform the clinical context for topical selection.
Niacinamide in Acne Management
The case for niacinamide in inflammatory acne vulgaris is established, and the mechanism is distinct from its role in pigmentation.
The most-cited clinical comparison is Shalita et al. (1995), which compared a 4% niacinamide gel against 1% clindamycin gel in moderate inflammatory acne over eight weeks. Both treatments produced equivalent reductions in inflammatory lesion count, with no statistically significant difference between groups. Clindamycin is an antibiotic. The equivalence of a non-antibiotic topical in inflammatory acne has direct implications for antimicrobial stewardship, which is a growing concern in UK dermatology and aesthetic medicine practice.
Niacinamide operates in acne primarily through sebum suppression and anti-inflammatory signalling rather than direct antimicrobial activity. This means it does not carry the resistance implications associated with topical antibiotics. Where antibiotic resistance is a concern, or where patients cannot yet tolerate retinoids, niacinamide is a reasonable adjunct or alternative within a topical protocol.
For aesthetic practitioners working in acne and PIH management, niacinamide sits comfortably alongside azelaic acid, salicylic acid, and adapalene in layered protocols. Its tolerability makes it particularly useful in patients whose skin cannot initially accommodate retinoids at standard concentrations. Acne Decoded covers the clinical reasoning behind the ingredient combinations most commonly used in this area.
Skin Barrier Function and Rosacea
Niacinamide's ceramide-upregulating mechanism has clinical relevance beyond pigmentation and acne. In rosacea and sensitive skin presentations, barrier dysfunction is a central feature. Compromised tight junctions and reduced ceramide levels allow irritants to penetrate more readily, amplifying inflammatory responses.
Clinical evidence for niacinamide in rosacea comes from a study examining a niacinamide-containing moisturiser over four weeks (Draelos et al., 2005). Participants showed reductions in blotchiness, skin dryness, and TEWL compared with baseline, consistent with the ceramide-upregulating mechanism. The study was industry-supported, a limitation the authors disclosed. The direction of benefit is consistent with the mechanistic picture and has not been contradicted in subsequent literature.
In clinical practice, this positions niacinamide as a useful component in homecare protocols for patients presenting with rosacea, particularly where barrier repair is the primary objective. Given that many rosacea patients are reactive to acids and retinoids at standard concentrations, the tolerability profile of niacinamide is a practical consideration in protocol design.
Concentration and Formulation
The concentrations tested across clinical trials range from 2% (barrier function studies) to 10% (hyperpigmentation RCTs in recent literature). Most positive outcomes in acne and PIH studies used 4-5%.
A few formulation points bear directly on how practitioners evaluate products:
Stability. Niacinamide is stable across a pH range of approximately 4-7, including at the acidic pH typical of toners and serums. This contrasts with ascorbic acid (vitamin C), which degrades rapidly below pH 3.5. It is one of the more formulation-stable actives available.
The niacinamide-vitamin C compatibility question. The claim that these two cannot be combined relates to a conversion at high concentrations (above 10%) where niacinamide can convert to niacin, causing transient flushing. At cosmeceutical concentrations of 2-5%, this conversion does not occur. The evidence base reviewed in Antioxidants (Boo, 2021) does not support the incompatibility claim at standard use concentrations.
Vehicle. Aqueous serums show adequate penetration in trials. Emulsified creams are appropriate where the occlusive component also supports TEWL reduction, such as in barrier-compromised or rosacea presentations.
For practitioners advising patients on homecare, concentrations of 4-5% are supported by the evidence for both hyperpigmentation and acne applications. The evidence base thins below 2% for clinical endpoints beyond barrier maintenance.
If you are working through how to build ingredient-led protocols that are grounded in the clinical literature, Acne Decoded covers this reasoning across the acne and PIH presentations most commonly seen in UK aesthetic practice.
FAQ
Is niacinamide prescription-only in the UK? No. Niacinamide is available in over-the-counter and cosmeceutical-grade products in the UK. Concentrations of 4-5% are widely available without a prescription. At these concentrations, it does not require a medical indication or prescriber involvement.
What is the difference between niacinamide and niacin? Niacinamide (nicotinamide) and niacin (nicotinic acid) are both forms of vitamin B3 but differ in their biological effects. Niacin causes vasodilation and cutaneous flushing. Niacinamide does not. At standard cosmeceutical concentrations, niacinamide does not convert to niacin in formulation, making it the preferred form for topical use.
Does niacinamide work across all Fitzpatrick phototypes? The clinical trial evidence includes patients with Fitzpatrick types II-VI, with several studies conducted specifically in populations where melasma and post-inflammatory hyperpigmentation are more prevalent, including higher phototype groups. There is no published evidence of reduced efficacy or increased adverse effects in higher phototype skin.
Is niacinamide appropriate for rosacea patients? Niacinamide is one of the few topical actives with both clinical evidence of benefit and a strong tolerability profile in rosacea. Its anti-inflammatory mechanism and barrier-supporting effects are directly relevant to rosacea pathophysiology. Clinical judgement applies, as with all topical interventions in reactive skin presentations.